232.21
0.52%
+1.20
After Hours:
232.21
Overview
News
Price History
Option Chain
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson & Co. stock is currently priced at $232.21, with a 24-hour trading volume of 1.42M.
It has seen a +0.52% increased in the last 24 hours and a -1.90% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $232.3 pivot point. If it approaches the $229.4 support level, significant changes may occur.
Becton Dickinson & Co. Stock (BDX) Financials Data
Becton Dickinson & Co. (BDX) Revenue 2024
BDX reported a revenue (TTM) of $19.49 billion for the quarter ending December 31, 2023, a +4.02% rise year-over-year.
Becton Dickinson & Co. (BDX) Net Income 2024
BDX net income (TTM) was $1.26 billion for the quarter ending December 31, 2023, a -22.04% decrease year-over-year.
Becton Dickinson & Co. (BDX) Cash Flow 2024
BDX recorded a free cash flow (TTM) of $2.65 billion for the quarter ending December 31, 2023, a +94.42% increase year-over-year.
Becton Dickinson & Co. (BDX) Earnings per Share 2024
BDX earnings per share (TTM) was $4.22 for the quarter ending December 31, 2023, a -20.38% decline year-over-year.
Becton Dickinson & Co. Stock (BDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Spoerel Thomas J | SVP,Controller&Chief Acct Off |
Mar 14 '24 |
Sale |
238.29 |
282 |
67,198 |
2,276 |
Garrison Michael David | EVP & President Medical |
Dec 11 '23 |
Sale |
232.46 |
1,239 |
288,018 |
7,274 |
Byrd Richard | EVP & President Interventional |
Nov 28 '23 |
Sale |
238.47 |
2,156 |
514,141 |
4,120 |
Goette Roland | EVP and President, EMEA |
Nov 16 '23 |
Option Exercise |
107.12 |
3,544 |
379,633 |
17,164 |
Byrd Richard | EVP & President Interventional |
Sep 05 '23 |
Sale |
274.48 |
459 |
125,986 |
3,444 |
Fraser Claire | Director |
Aug 28 '23 |
Sale |
281.66 |
848 |
238,848 |
21,608 |
Hickey David | EVP & President, Life Sciences |
Aug 11 '23 |
Option Exercise |
132.54 |
3,883 |
514,653 |
9,030 |
Hickey David | EVP & President, Life Sciences |
Aug 11 '23 |
Sale |
277.85 |
2,974 |
826,326 |
4,199 |
Garrison Michael David | EVP & President Medical |
Aug 08 '23 |
Sale |
277.13 |
1,300 |
360,269 |
5,157 |
Becton Dickinson & Co. Stock (BDX) Latest News
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
Zacks Investment Research
ClearBridge Appreciation Strategy Q1 2024 Portfolio Manager Commentary
Seeking Alpha
BD's (BDX) Latest Product to Offer Wider Access to Researchers
Zacks Investment Research
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
Zacks Investment Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Zacks Investment Research
AngioDynamics (ANGO) Settles Patent Litigations With BD
Zacks Investment Research
About Becton Dickinson & Co.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Cap:
|
Volume (24h):